Lrig1 antibody (AA 1001-1093)
Quick Overview for Lrig1 antibody (AA 1001-1093) (ABIN735263)
Target
See all Lrig1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 1001-1093
-
Cross-Reactivity
- Human, Mouse, Rat
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human LRIG1
-
Isotype
- IgG
-
-
-
-
Application Notes
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Expiry Date
- 12 months
-
-
-
: "Lrig1 is a positive prognostic marker in hepatocellular carcinoma." in: OncoTargets and therapy, Vol. 9, pp. 7071-7079, (2016) (PubMed).
-
: "Lrig1 is a positive prognostic marker in hepatocellular carcinoma." in: OncoTargets and therapy, Vol. 9, pp. 7071-7079, (2016) (PubMed).
-
- Lrig1 (Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1))
-
Alternative Name
- LRIG1
-
Background
-
Synonyms: LIG1, LIG-1, Leucine-rich repeats and immunoglobulin-like domains protein 1, LRIG1
Background: Acts as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.
-
Gene ID
- 26018
-
UniProt
- Q96JA1
Target
-